Literature DB >> 3886376

Clinical applications of monoclonal antibodies.

H Krakauer.   

Abstract

This review highlights the properties, problems, and potentials of monoclonal antibodies as diagnostic and therapeutic agents. The most extensive experience has been obtained with antibodies specific for functionally distinct subsets of lymphocytes. They have been used to monitor the immunosuppression of organ-graft recipients and to attempt to elucidate the disturbance of immunologic function in a variety of conditions. Current therapeutic applications under trial include immunosuppression to treat organ-graft rejection and to eliminate cells responsible for graft-vs-host disease from the bone marrow. Applications to cancer diagnosis and treatment have been hampered by the difficulty of identifying truly tumor-specific antigens. Successes have, however, been obtained in the location of metastases and in the extracorporeal treatment of autologous marrow to purge it of malignant cells, and, more rarely, with the direct administration of monoclonal antibodies in vivo. The conjugation of cell-type specific monoclonal antibodies with cytotoxic agents should overcome a number of limitations.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3886376     DOI: 10.1007/bf02148651

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  49 in total

Review 1.  Hybridomas: a new dimension in biological analyses.

Authors:  R H Kennett
Journal:  In Vitro       Date:  1981-12

2.  High-affinity monoclonal antibodies to the cardiac glycoside, digoxin.

Authors:  M M Hunter; M N Margolies; A Ju; E Haber
Journal:  J Immunol       Date:  1982-09       Impact factor: 5.422

3.  T lymphocyte subsets in uveitis.

Authors:  R B Nussenblatt; M Salinas-Carmona; W Leake; I Scher
Journal:  Am J Ophthalmol       Date:  1983-05       Impact factor: 5.258

4.  Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies.

Authors:  W Gerhard; J Yewdell; M E Frankel; R Webster
Journal:  Nature       Date:  1981-04-23       Impact factor: 49.962

5.  Anti-idiotypic antibodies to HLA-DR4 and DR2.

Authors:  E Reed; V Bonagura; P Kung; D W King; N Suciu-Foca
Journal:  J Immunol       Date:  1983-12       Impact factor: 5.422

6.  Con A-inducible suppression of MLC: evidence for mediation by the TH2 + T cell subset in man.

Authors:  E L Reinherz; S F Schlossman
Journal:  J Immunol       Date:  1979-04       Impact factor: 5.422

7.  Production of human hybridomas secreting antibodies to measles virus.

Authors:  C M Croce; A Linnenbach; W Hall; Z Steplewski; H Koprowski
Journal:  Nature       Date:  1980-12-04       Impact factor: 49.962

8.  Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders.

Authors:  J L Fahey; H Prince; M Weaver; J Groopman; B Visscher; K Schwartz; R Detels
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

9.  Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity.

Authors:  L Olsson; H S Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

10.  Changes in T-cell subsets in patients with rheumatoid arthritis treated with total lymphoid irradiation.

Authors:  B L Kotzin; G S Kansas; E G Engleman; R T Hoppe; H S Kaplan; S Strober
Journal:  Clin Immunol Immunopathol       Date:  1983-05
View more
  3 in total

Review 1.  Infectious disease therapy in the 1990s. Where are we heading?

Authors:  M Rozenberg-Arska; M R Visser
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

Review 2.  Prospects for monoclonal antibodies in the diagnosis and treatment of bacterial infections.

Authors:  J Verhoef; R Torensma
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-04       Impact factor: 3.267

3.  Monoclonal antibodies and immobilized antibodies. Patents and literature.

Authors:  R J Linhardt
Journal:  Appl Biochem Biotechnol       Date:  1987-06       Impact factor: 2.926

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.